1
|
Shukla V, Cheng S, Hukin J, Huh L, Datta AN. Developmental and epileptic encephalopathies after successful treatment of pediatric ALL: A case series and review of literature. Epileptic Disord 2024. [PMID: 39258473 DOI: 10.1002/epd2.20280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2024] [Revised: 08/12/2024] [Accepted: 08/27/2024] [Indexed: 09/12/2024]
Abstract
Successful treatment of acute lymphoblastic leukemia (ALL) requires multiagent chemotherapy regimens and central nervous system prophylaxis, including intrathecal methotrexate. Although acute symptomatic seizures can occur during ALL treatment, epilepsy is less common. Furthermore, drug resistant epilepsy (DRE) is rare, presenting with two phenotypes: focal epilepsy, such as temporal lobe, or epileptic encephalopathies (EE), such as Lennox-Gastaut syndrome (LGS). For ALL survivors, the development of DRE has significant impact on morbidity, mortality, and quality of life. We describe four patients with ALL remission, who developed EEs, of which 3 had LGS. Mean age at ALL diagnosis was 1.9 years; range 1.1-2.5 years. All, but one, had normal development prior to ALL. No patient had CNS leukemic involvement. All patients received CNS prophylaxis with intrathecal methotrexate, without cranial radiotherapy. Three had symptomatic methotrexate neurotoxicity during treatment. The mean age at first seizure was 5.6 years; range 3.9-7.5 years, with a mean latency of 3.7 years from ALL diagnosis. All patients developed drug resistant EEs, moderate intellectual disability, and neuropsychiatric co-morbidities. Two patients had a minimal response to corpus callosotomy (CC), and one did not respond the ketogenic diet. Successful treatment of childhood ALL is rarely associated with the development of DRE and EEs. Young age at ALL diagnosis (<3 years) may be a predisposing factor. Palliative treatments, including ketogenic diet and CC have limited benefit in these patients. Individual genetic susceptibility to MTX toxicity is likely related to epileptogenesis, and further research is required for epilepsy biomarkers.
Collapse
Affiliation(s)
- Vanita Shukla
- Department of Pediatrics, Division of Neurology, Faculty of Medicine, BC Children's Hospital, University of British Columbia Vancouver, Vancouver, British Columbia, Canada
| | - Sylvia Cheng
- Department of Hematology, Oncology, BMT, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Juliette Hukin
- Department of Pediatrics, Division of Neurology, Faculty of Medicine, BC Children's Hospital, University of British Columbia Vancouver, Vancouver, British Columbia, Canada
- Department of Hematology, Oncology, BMT, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Linda Huh
- Department of Pediatrics, Division of Neurology, Faculty of Medicine, BC Children's Hospital, University of British Columbia Vancouver, Vancouver, British Columbia, Canada
| | - Anita N Datta
- Department of Pediatrics, Division of Neurology, Faculty of Medicine, BC Children's Hospital, University of British Columbia Vancouver, Vancouver, British Columbia, Canada
| |
Collapse
|
2
|
Jaafar F, Abboud MR, Obeid M. Causes of New-Onset Seizures and Their Treatment in Children With Non-CNS Malignancies: A Retrospective Study in a Tertiary Care Center. Pediatr Neurol 2022; 137:17-21. [PMID: 36182697 DOI: 10.1016/j.pediatrneurol.2022.08.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Revised: 08/20/2022] [Accepted: 08/29/2022] [Indexed: 10/14/2022]
Abstract
BACKGROUND Seizures occur in up to 13% of children with non-central nervous system (CNS) malignancies, but little is known about their causes and optimal diagnostic and therapeutic approaches. Here we sought to determine etiologies and clinical trajectories of new-onset seizures in this patient population. METHODS A retrospective chart review over a 10-year period was conducted at the American University of Beirut Medical Center to identify children with non-CNS malignancies and at least one new-onset seizure. Data were collected on the underlying malignancy, seizure etiology, clinical course, treatments, electroencephalograms, and brain imaging. RESULTS New-onset seizures occurred in 56 children (2-year median follow-up), most commonly in the context of acute lymphoblastic leukemia, lymphomas, and sarcomas. In 19 children, the first seizure consisted of status epilepticus. The most common etiologies were cerebrovascular accidents, posterior reversible encephalopathy syndrome, and metastasis. Forty-nine patients received anti-seizure medications (ASMs). Withdrawal of ASMs was successful in 19 children with normal initial or follow-up brain imaging but failed in three patients with persistent brain lesions. The remaining children, all of whom except two had structural brain abnormalities, received chronic ASMs and remained seizure free for a median period of 2 years at the last follow-up in survivors. CONCLUSIONS Not only are seizures in children with non-CNS cancers often indicative of a serious brain insult, but they can also be challenging in the form of status epilepticus. An urgent diagnostic evaluation is therefore needed to expedite treatment, which should be tailored to the chronicity of the underlying cause.
Collapse
Affiliation(s)
- Fatima Jaafar
- Division of Child Neurology, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon
| | - Miguel R Abboud
- Division of Hematology-Oncology, Department of Pediatrics and Adolescent Medicine, Children's Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon
| | - Makram Obeid
- Division of Child Neurology, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Department of Anatomy, Cell biology and Physiological Sciences, American University of Beirut, Beirut, Lebanon.
| |
Collapse
|
3
|
Characterizing the phenotype of drug-resistant childhood epilepsy associated with leukemia: A case series. Epilepsy Behav Rep 2021; 15:100432. [PMID: 33898963 PMCID: PMC8053798 DOI: 10.1016/j.ebr.2021.100432] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2020] [Revised: 01/08/2021] [Accepted: 01/14/2021] [Indexed: 11/20/2022] Open
Abstract
Two phenotypes of drug-resistant epilepsy were noted in children with prior leukemia, focal epilepsy, and epileptic encephalopathy in the form of Lennox-Gastaut syndrome. Temporal lobectomy was effective in two children with mesial temporal sclerosis. Corpus callosotomy and vagus nerve stimulation was tried in children with epileptic encephalopathy with variable outcomes.
Children with leukemia are at risk for epilepsy due to primary disease or neurotoxic therapies. We describe the phenotypes of drug-resistant epilepsy in 10 children with history of leukemia. Of 10 cases, 6 had features of Lennox-Gastaut syndrome, and 4 had focal epilepsy. Mean age of epilepsy onset was 5 years in Lennox-Gastaut cases and 6.5 years in focal epilepsy cases. Mean latency between leukemia diagnosis and seizure onset was about 3 years. Brain MRI of 2 patients with epileptic encephalopathy had structural abnormalities – unclear if causative for epilepsy, and 4 had no overt structural abnormalities. In focal epilepsy group, 3 had temporal lobe epilepsy and one had fronto-temporal localization. All 10 patients had received intrathecal chemotherapy; 2 also had received whole brain irradiation. Seizures were poorly controlled in the epileptic encephalopathy group. Three underwent corpus callosotomy with variable response. Two patients with temporal lobe epilepsy had temporal lobectomy with Engel 1 outcome at 2 year follow-up in both. Two phenotypes of refractory epilepsy were observed in children with previous history of leukemia, focal epilepsy and epileptic encephalopathy. Children with temporal lobe epilepsy had good response to temporal lobectomy; response to palliative surgery was variable.
Collapse
|
4
|
Leng Y, Yu T, Li Y, Chen W. Surgical treatment of refractory epilepsy after chemotherapy in two children with leukemia. EPILEPSY & BEHAVIOR CASE REPORTS 2013; 1:32-4. [PMID: 25667821 PMCID: PMC4150597 DOI: 10.1016/j.ebcr.2012.12.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/02/2012] [Revised: 12/18/2012] [Accepted: 12/19/2012] [Indexed: 11/26/2022]
Abstract
Refractory epilepsy is a rare, long-term complication in children with acute leukemia who are receiving chemotherapy. A few studies have reported cases of several patients who developed recurrent complex partial seizures after the initiation of chemotherapy. In these cases, the cause of the refractory seizures was identified as mesial temporal lobe sclerosis. Here, we report on two patients with extratemporal lesions accompanied by refractory seizures, a long-term complication of acute lymphocytic leukemia. Using presurgical evaluations and measures of the surgical outcomes, the lesions were identified as epileptogenic and were located in the mesial temporal lobe. The underlying pathophysiological background is discussed to aid in understanding this uncommon long-term complication.
Collapse
Affiliation(s)
- Yun Leng
- Department of Hematology, Chaoyang Hospital of Capital Medical University, Beijing, China
| | - Tao Yu
- Beijing Institute of Functional Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China
| | - Yongjie Li
- Beijing Institute of Functional Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China
| | - Wenming Chen
- Department of Hematology, Chaoyang Hospital of Capital Medical University, Beijing, China
| |
Collapse
|
5
|
Armstrong GT, Conklin HM, Huang S, Srivastava D, Sanford R, Ellison DW, Merchant TE, Hudson MM, Hoehn ME, Robison LL, Gajjar A, Morris EB. Survival and long-term health and cognitive outcomes after low-grade glioma. Neuro Oncol 2011; 13:223-34. [PMID: 21177781 PMCID: PMC3064628 DOI: 10.1093/neuonc/noq178] [Citation(s) in RCA: 154] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2010] [Accepted: 10/23/2010] [Indexed: 11/13/2022] Open
Abstract
Long-term morbidity for children with low-grade glioma (LGG) requires exposure-specific characterization. Overall survival (OS) and progression-free survival (PFS) were estimated for 361 children diagnosed with LGG between 1985 and 2007 at a single institution. Five-year survivors (n = 240) received risk-based clinical assessment. Cumulative incidence of late effects 15 years from diagnosis were estimated. Risk factors for adverse health were identified using Fine and Gray's approach to Cox's proportional hazards model, accounting for death as a competing risk. OS at 15 years was 86% (95% confidence interval [CI] 82%-90%), and PFS was 55% (95% CI 51%-58%). Among the 240 5-year survivors, the 5-, 10-, and 15-year cumulative incidence of adverse outcomes included blindness: 10%, 13%, and 18%, respectively; hearing loss: 8%, 14%, and 22%; obesity/overweight: 18%, 35%, and 53%; hyperinsulinism: 1%, 5%, and 24%; growth hormone deficiency: 13%, 27%, and 29%;thyroid hormone deficiency: 16%, 28%, and 33%; and adrenocorticotropic hormone (ACTH) deficiency: 12%, 22%, and 26%. Multivariable models demonstrated radiation therapy to be a significant independent predictor of hearing loss, growth hormone deficiency, abnormal thyroid function, and ACTH deficiency. Diencephalic location was a statistically significant independent risk factor for blindness, growth hormone deficiency, abnormal thyroid function, and ACTH deficiency. Among the 182 5-year survivors assessed for intellectual function, 34% had an intelligence quotient (IQ) below average (<85), associated with younger age at diagnosis, epilepsy, and shunt placement. Survivors of childhood LGG experience substantial long-term adverse effects that continue to increase well beyond the 5-year survival time point.
Collapse
Affiliation(s)
- Gregory T Armstrong
- Department of Epidemiology & Cancer Control, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 735, Memphis, TN 38105, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Successful surgical treatment of medically refractory epilepsy after chemotherapy in a child with leukemia: a case report. Neurologist 2010; 16:41-3. [PMID: 20065796 DOI: 10.1097/nrl.0b013e31819b9d17] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
INTRODUCTION Mesial temporal sclerosis associated with acute lymphoblastic leukemia has been rarely reported. CASE REPORT We report a case of a 15-year-old boy with acute lymphoblastic leukemia who developed medically refractory temporal lobe epilepsy in a long time period after chemotherapy, and successfully treated with surgical resection. CONCLUSIONS To our knowledge, this is the first description of a leukemic child with medically refractory temporal lobe epilepsy who achieved seizure-freedom postoperatively during the long-term follow-up. The clinical history and details of the underlying pathophysiological background and treatment of this complication are discussed in this case report.
Collapse
|
7
|
Eshelman-Kent D, Gilger E, Gallagher M. Transitioning Survivors of Central Nervous System Tumors: Challenges for Patients, Families, and Health Care Providers. J Pediatr Oncol Nurs 2009; 26:280-94. [DOI: 10.1177/1043454209343209] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Survivors of central nervous system tumors (SCNST) are a growing group of cancer survivors who require risk-based, long-term health care due to the chemotherapy, surgery, and radiation they have received.Although treatment strategies are being developed to reduce morbidity and mortality, ultimately this subgroup of pediatric cancer survivors often faces moderate to severe late effects of their treatment.As a result, they will need lifelong health care that includes risk-based health care due to cancer treatment exposures as well as primary adult health care, including primary and secondary preventative care. The best way to accomplish lifelong health care for SCNST as they enter adulthood is not clearly defined. In this article, the authors plan to (1) present an overview of the complexities of health care problems that make transition challenging for SCNST; (2) review the evolving transition literature; (3) explore the barriers to successful transition; (4) discuss methods to facilitate transition; (5) describe approaches, strategies, and models for survivorship care in SCNST; (6) present issues for consideration when transitioning SCNST; and (7) provide information on transition-related resources.
Collapse
Affiliation(s)
- Debra Eshelman-Kent
- ATP Five Plus Cancer Survivor Program, Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, 3333 Burnett Avenue, MLC 11013, Cincinnati, OH 45229-3039,
| | | | | |
Collapse
|
8
|
Intractable epilepsy in patients treated for childhood acute lymphocytic leukemia. Seizure 2009; 18:298-302. [DOI: 10.1016/j.seizure.2008.10.008] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2008] [Accepted: 10/23/2008] [Indexed: 12/17/2022] Open
|
9
|
Iwakawa M, Takai N, Goto M, Noda S, Ando K, Imai T. Strain-dependent differences in locomotor activity after local brain irradiation with 30 GyE of carbon ions. Exp Anim 2005; 54:447-50. [PMID: 16365522 DOI: 10.1538/expanim.54.447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
This study investigated strain differences in brain damage among male A/J, C57BL/6JNrs and C3H/HeNrs mice after local brain irradiation. Whole brains were irradiated with a single dose of 30 GyE carbon ion beams and then locomotor activity was determined as body heat of each animal. The daily locomotor activities of untreated mice differed among strains. Non-irradiated C57BL/6JNrs mice were more active than A/J mice. This variance became more obvious immediately after irradiation, when the activity of A/J and C3H/HeNrs mice diminished, whereas that of C57BL/6JNrs mice increased at the beginning of the active phase and remained elevated for three days after irradiation. The altered activities of all three strains of irradiated mice gradually recovered to normal within three to four days.
Collapse
Affiliation(s)
- Mayumi Iwakawa
- Frontier Research Center, National Institute of Radiological Institute, Anagawa, Inage-ku, Chiba, Japan
| | | | | | | | | | | |
Collapse
|